New FDA Approval: Osimertinib (TAGRISSO®) Combined with Chemotherapy for Treating EGFR-Mutated NSCLC Non-Small Cell Lung Cancer 4 Mins Read19 On February 16, 2024, the Food and Drug Administration (FDA) announced the approval of osimertinib, marketed under the brand name…
Tagrisso the Final ADAURA OS Analysis in Stage IB to IIIA EGFR-Mutated NSCLC Non-Small Cell Lung Cancer 3 Mins Read9 Roy Herbst, MD, PhD, from the Yale Cancer Center and Yale School of Medicine, presented a groundbreaking abstract at the…
